ARway.ai Spatial Computing Solution Gaining Momentum As 2023 Sales Pipeline Reaches Over $2.5M in Revenue Potential

Sales Pipeline Jumps Over +70% in 6-Week Period

ARway.ai ("ARway" or the "Company") (CSE:ARWY)(OTCQB:ARWYF)(FSE:E65), an AI powered Augmented Reality Experience platform with a disruptive no-code, no beacon spatial computing solution, enabled by visual marker tracking with centimeter precision, is pleased to announce that its sales pipeline has jumped over 70% in just six weeks to over $2.5 million in potential enterprise contracts. These enterprise deals represent a significant revenue opportunity for ARway.ai as it expands its reach across the globe in the indoor navigation industry. The Company is in late stage negotiations with a number of enterprise accounts and expects to continue building its pipeline of sales opportunities throughout the year

On May 11, ARway.ai announced it had reached a pipeline total of $1.4 million. Today's announcement of the increased pipeline to $2.5 million highlights a momentous achievement that serves as a testament to the surging interest from enterprises across diverse industries in ARway.ai's groundbreaking technology. The pipeline has experienced exponential growth, expanding by an astonishing $1 million (or 70%) in a mere six weeks. The remarkable growth in customer interest and the ever-expanding pipeline have galvanized the Company to establish an objective of concluding the year 2023 with a robust pipeline valued at $10 million, primed to drive further success into 2024. ARway.ai remains committed to pushing the boundaries of AR innovation and delivering exceptional value to its clients through cutting-edge solutions. The remarkable increase in enterprise interest underscores the recognition of ARway.ai's technological prowess and the immense potential it holds in revolutionizing AR experiences and indoor navigation.

Evan Gappelberg, the CEO of ARway.ai, provided his insights, saying, "We acknowledge that the $2.5 million currently in our pipeline does not offer an assurance of sales. However, we maintain a high level of confidence in our team's ability to achieve a considerable conversion rate and successfully close these deals. It is important to note that enterprise contracts, such as the ones we are presently pursuing, typically involve an extended sales cycle and necessitate a greater investment of time. We have diligently engaged in piloting, developing, and negotiating with these esteemed enterprise customers over an extended duration, thereby establishing a foundation of trust and progress."

He continued, "While we cannot guarantee outcomes, we are very optimistic about our ability to obtain a noteworthy closing ratio on this thriving and expanding pipeline. Additionally, our upcoming collaborations with Magic Leap, Microsoft HoloLens, and the recently announced Apple Vision Pro hold the potential to propel our business and further expedite our pipeline's growth. We eagerly anticipate unveiling significant deals in the second half of 2023."

There have been a number of notable catalysts, which has increased pipeline growth significantly, with $1M in growth in the last 6 weeks alone:

13 corporations identified as pilot project prospects
Opportunities across major vertical markets such as retail, healthcare, education, manufacturing, telecom, and digital marketing firms
Medium-sized and large enterprise customers
Newly released Referral Partner and Service Provider Partner programs; with 12 partner program prospects currently evaluating the platform
New pricing and go-to-market strategies including integration and app development for various AR glasses manufacturers

This announcement comes after a number of exciting updates for the Company. As recently announced, the release of the integration with Magic Leap and Microsoft HoloLens AR glasses is a game changer for ARway.ai. With the integration, ARway.ai will provide a software package for agencies, brands and corporations to create and publish large-scale location persistent AR experiences to these AR glasses from the ARway platform, leveraging ARway's computer vision and extended tracking technologies.

In addition, the recent announcement of the Apple Vision Pro will have a significant impact for ARway.ai. It is anticipated that adoption of "Apple Vision Pro" will be a massive boost for the augmented reality industry, opening up a large new market opportunity for ARway's technology. ARway is a provider of the software solution for the Apple Vision Pro. Apple's visionOS operating system natively supports the Unity 3D engine and RealityKit (formally ARkit) enabling ARway to seamlessly distribute its technology through existing and new applications in iOS.

ARway.ai also has had a number of technology enhancements, including the update to SDK 2.3, and another update (SDK 2.5) is expected to be announced in the coming months. The overall V2.5 platform update is expected to be announced shortly. The Company has also recently filed a provisional patent for its ground-breaking technology, "Device Localization based on Computer Vision and Visual Inertial Odometry." This latest provisional patent is the second in a series of patents planned to secure ARway's groundbreaking technology. This pioneering system tackles one of AR's most notable challenges, ensuring large-scale location persistence in indoor spaces without the need for expensive retrofitting. Instead, ARway's patent-pending technology harmoniously integrates visual markers, such as QR codes or other identifiable 2D objects in the physical environment, with an online map database.

The Company believes that its technological advances and new market opportunities, as well as the integration with prominent AR glasses providers and recent uplift to the OTCQB, has solidified consumer confidence in its products and anticipates the pipeline will increase over the coming months.

Recent News

To learn more about ARway, please follow on Social Media: Twitter, YouTube, Instagram, LinkedIn, and Facebook, and visit our website: www.arway.ai.

About ARway.ai

ARway.ai (CSE: ARWY) (OTCQB: ARWYF) (FSE: E65) is a spatial computing platform powered by artificial intelligence (AI) providing an array of augmented reality (AR) experiences for indoor spaces. ARway's breakthrough no-code no-beacon IPNN allows for the easy creation of navigation, tours, information sharing, notifications, advertising and gamification. ARway works seamlessly as a cross platform solution on iOS/ Android. ARway's technology is optimized for both mobile devices and AR glasses: Apple's Vision Pro, Magic Leap and Microsoft's HoloLens. ARway has unlimited use cases for augmenting physical spaces, making it a valuable tool for creators, brands and companies in various industries. The complete ARway platform includes: the Web Creator Studio, the ARwayKit Software Development Kit (SDK) and a mobile app for iOS and Android.

Nextech 3D.ai
On October 26, 2022, ARway.ai. was spun-out from its parent Company, Nextech3D.ai (OTCQX: NEXCF) (CSE: NTAR) (FSE: EP2). Nextech retained a control ownership in ARway.ai. with 13 million shares, or a 50% stake. Nextech3D.ai is a Metaverse Company and leading provider of augmented reality ("AR") experience technologies and 3D model services. Nextech's AI-powered 3D modeling platform, "ARitize3D" has contracts with; AMZN, KSS, CB2, Genuine Parts & many others. To learn more about Nextech3D.ai, visit www.nextechar.com

For further information, please contact:

Investor Relations Contact
Julia Viola
investor.relations@arway.ai

ARway.ai
Evan Gappelberg
CEO and Director
866-ARITIZE (274-8493)

Forward-Looking Statements

The CSE has not reviewed and does not accept responsibility for the adequacy or accuracy of this release.

Certain information contained herein may constitute "forward-looking information" under Canadian securities legislation. Generally, forward-looking information can be identified by the use of forward-looking terminology such as, "will be" or variations of such words and phrases or statements that certain actions, events or results "will" occur. Forward-looking statements regarding the completion of the transaction are subject to known and unknown risks, uncertainties and other factors. There can be no assurance that such statements will prove to be accurate, as future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking statements and forward-looking information. ARway.ai will not update any forward-looking statements or forward-looking information that are incorporated by reference herein, except as required by applicable securities laws.

SOURCE:Arway Corporation

View source version on accesswire.com:
https://www.accesswire.com/763770/ARwayai-Spatial-Computing-Solution-Gaining-Momentum-As-2023-Sales-Pipeline-Reaches-Over-25M-in-Revenue-Potential

News Provided by ACCESSWIRE via QuoteMedia

ARway.ai ARWY:CC OTC:ARWYF Emerging Tech Investing

ARWY:CC

ARway.ai Signs Deal with George Mason University for Augmented Reality Campus Navigation and Experience

ARway.ai ("ARway" or the "Company") (CSE:ARWY)(OTCQB:ARWYF)(FSE:E65) is an AI powered Augmented Reality Experience platform with a disruptive no-code, no beacon spatial computing solution enabled by visual marker tracking with centimeter precision is pleased to announce that George Mason University is signed up for the ARway platform and will be deploying ten spatial maps across the university campus. The rollout is part of a 2024 project aimed at enhancing the campus navigation and campus experience for students. GMU has an undergraduate enrollment of approximately 27,014 and the campus size is 817 acres. ARway.ai is seeing demand from across the globe for University Campus deployments, and is currently deployed in the Middle East at the Suleyman Demirel University in Turkey, In the EU at the Institut für Innovations- und Informationsmanagement (iFii), University of Applied Sciences Brandenburg. ARway has also signed multiple new subscriptions with prestigious universities around the globe including Bicol University in Indonesia, DHA Suffa University in Pakistan, University of Alberta in Canada, University College Cork in the UK and German University of Technology in Oman

News Provided by ACCESSWIRE via QuoteMedia

Keep reading...Show less

Sona's Cancer Therapy Triggers Abscopal Effect, Eliminating Distant Tumors In Preclinical Melanoma Study

Sona Nanotech Inc. (CSE: SONA) (OTCQB: SNANF) (the "Company" or "Sona") is pleased to announce that a detailed biomarker analysis of the recently reported pre-clinical melanoma study conducted at Dalhousie University (the "Study") indicates that, beyond shrinking tumors on its own, Sona's Targeted Hyperthermia Therapy ("THT") also stimulates the innate immune system to target and eliminate untreated (contralateral) tumors when combined with a standard immunotherapeutic drug, IL-2. (See figure #1, below.) On the basis of efficacy data achieved in two different murine cancer models (triple negative breast cancer and malignant melanoma), the Company is now proceeding with safety and biocompatibility testing that will be required by regulating agencies to enter into human studies.

News Provided by Newsfile via QuoteMedia

Keep reading...Show less

PRINCIPAL TECHNOLOGIES ANNOUNCES CLOSING OF FIRST TRANCHE OF PRIVATE PLACEMENT

Principal Technologies Inc. (the " Company ") (TSXV: PTEC) (FSE: J07), is pleased to announce the closing of the first tranche (" Tranche 1 ") of its previously announced non-brokered private placement (the " Offering ") with one investor, MRPT Invest UG (" MRPT "), a company owned and controlled by Markus Mair . The Company issued a total of 4,000,000 units at $0.25 per unit for gross proceeds of $1,000,000 . Each unit (a " Unit ") will consist of one common share (a ' Share ") of the Company and one common share purchase warrant (a " Warrant "). Each Warrant entitles the holder to purchase one additional Share of the Company at $0.30 for a period of two (2) years from the date of closing. The Warrants are subject to a blocker term that prohibits exercise of the Warrants to the extent the holder would as a result of any exercise exceed 19.99% of then issued Shares.

News Provided by Canada Newswire via QuoteMedia

Keep reading...Show less

Sona's Therapy Shows Significant Preclinical Efficacy in Second Cancer

Sona Nanotech Inc. (CSE: SONA) (OTCQB: SNANF) (the "Company" or "Sona") is pleased to announce that its targeted hyperthermia therapy ("THT") demonstrated positive results in a second preclinical cancer model. Findings just presented at the 2024 STING & TLR Targeted Therapies Summit for immunotherapies in San Diego, California, show that Sona's THT achieved responses in a preclinical melanoma model equal to that which was recently reported from its triple negative breast cancer study. THT effectively treated melanoma tumors in all animals when administered on its own. Further, when THT was combined with doses of interleukin-2 ("IL-2"), a standard immunotherapy, a synergistic effect was shown whereby greater treatment response, measured by tumor volume reduction, was achieved in comparison to either approach alone.